Critical Review: MiMedx Group (MDXG) versus Baxter International (BAX)
Baxter International (NYSE: BAX) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Baxter International pays an annual dividend of $0.64 per share and has a dividend yield of 1.0%. MiMedx Group does not pay a dividend. Baxter International pays out 38.8% of its earnings in the form of a dividend.
Baxter International has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.
Valuation & Earnings
This table compares Baxter International and MiMedx Group’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Baxter International||$10.28 billion||3.31||$2.23 billion||$1.65||37.90|
|MiMedx Group||$283.32 million||5.00||$32.97 million||$0.19||69.53|
Baxter International has higher revenue and earnings than MiMedx Group. Baxter International is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
83.6% of Baxter International shares are held by institutional investors. Comparatively, 60.4% of MiMedx Group shares are held by institutional investors. 0.1% of Baxter International shares are held by company insiders. Comparatively, 12.4% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Baxter International and MiMedx Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for Baxter International and MiMedx Group, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Baxter International currently has a consensus price target of $65.73, indicating a potential upside of 5.11%. MiMedx Group has a consensus price target of $16.00, indicating a potential upside of 21.12%. Given MiMedx Group’s stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Baxter International.
MiMedx Group beats Baxter International on 9 of the 16 factors compared between the two stocks.
Baxter International Company Profile
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision.
MiMedx Group Company Profile
MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.
Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.